GlaucomaSPARCSNCT02627339
Building a Database of Results From People Without Eye Problems
An observational study of Glaucoma, run by Wills Eye at 1 site in United States.
Trial summary
The purpose of this study is to build a database of results from a new test that measures contrast sensitivity (the Spaeth-Richman Contrast Sensitivity Test (SPARCS)). Contrast sensitivity is an important part of your ability to see. Read more about this study
- Who is it for?
- Ages 10 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Glaucoma
- How many people
- 208 participants
- Where
- 1 siteUnited States
- Study dates
- Aug 2012to Aug 2015
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 90 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Healthy controls with no eye diseases
Who may be able to join
- 10 years or older and healthy
- No eye diseases
Who cannot join
- Patients with glaucoma, macular degeneration, diabetic retinopathy, corneal disease, eye movement disorders or any eye disease causing vision loss
- Patients with visual acuity worse than 20/40
- Patients with cataracts or opacities 2+ or greater
- Patients with refractive error +6 -6 or greater
Trial locations and contacts
1 site in 1 country.
United States1 site
Wills Eye Glaucoma Service
Philadelphia, Pennsylvania, 19107
About this study
Official title: A Prospective Study of Controls to Build a Normative Database for the Spaeth/Richman Contrast Sensitivity Test (SPARCS)
The purpose of this study is to build a database of results from a new test that measures contrast sensitivity (the Spaeth-Richman Contrast Sensitivity Test (SPARCS)). Contrast sensitivity is an important part of your ability to see. When contrast sensitivity decreases, you are less able to see objects and detect motion. For instance, if you have decreased contrast sensitivity, you might be less able to read, see in the dark, drive, hit a ball, or walk safely. Decrease in contrast sensitivity leads to a decrease in quality of life.
Read the detailed description
Objective: To build a normative database for the Spaeth / Richman Contrast Sensitivity Test (SPARCS).
Background: Patients with glaucoma have diminished contrast sensitivity. SPARCS is a novel test designed to determine the contrast threshold in the central 5 degrees of vision as well as each of the 4 peripheral quadrants (superotemporal, superonasal, inferotemporal, inferonasal). It is performed on a standard computer with at least 1024 x 768 monitor resolution. The correct testing distance is 50 cm away from the computer screen. Appropriate refractive correction is used. Testing is performed in a room with standardized lighting (85 cd / m2) and no windows in order to minimize glare and reflections. Testing is performed monocularly with the non-tested eye covered by an eye patch. The purpose of this study is to build a normative database for SPARCS.
Study Design: Cross sectional observational study.
Methods: Healthy volunteers will be recruited from the Wills Eye Institute after obtaining informed consent following the principles of the Helsinki Convention. Approximately 320 people free of ocular disease will be recruited to form a portion of the normative database for SPARCS. A goal of 20 subjects per decade of life (10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+) for both Caucasians and African Americans will be recruited. Other ethnicities will also be recruited, though without specific recruitment goals. Future study locations will help diversify the population of the normative database.
After agreeing to participate in the study, subjects will be assessed to determine if they qualify. Potential participants will be asked if they have any known eye diseases or decreased vision. Best-corrected monocular visual acuities will be assessed using an ETDRS visual acuity chart. A slit lamp examination will be performed to confirm good ocular health. Subjects will be excluded if they have any apparent ocular disease that affects visual acuity or visual function. For example, people with glaucoma, macular degeneration, or diabetic retinopathy will be excluded. Additional exclusion criteria includes: visual acuity 20/40 or worse; cataract grade 2 3+ or worse; posterior capsular opacity grade 2 3+ or worse; refractive error greater than +5 or -5 diopters; and incisional eye surgery within the prior 3 months.
After a person qualifies for the normative database, he or she will then take SPARCS. A trained technician will position the patient to the correct testing distance, check room lighting, and then explain the test. Subjects will be told to fixate on the central area and when ready, click the central area once with a computer mouse. Vertical dark bars will briefly appear in 1 of the 5 tested areas on the computer monitor. A subject will then move the mouse to the area the image appeared and click it once. When the subject is ready for the next image to appear, he or she will click again on the central area. Subjects are also instructed to guess where the image appeared if unsure. Vertical square waves of varying contrast levels will then continue to appear in a random pattern until threshold has been reached for each area. After the testing algorithm has been completed, the test will automatically end.
Each eye of an eligible subject will take the test twice after receiving instructions from a technician. The technician will remain in the testing room the first two times SPARCS is taken. A half hour later, the subject will then take SPARCS again without instructions from the technician and without the technician being present in the room.
The mean score and standard deviation of each area and the total score will be analyzed for age, gender, race, and lens status. Spearman correlations will be used to examine continuous variables and Kruskal-Wallis analysis for categorical measures. Test-retest repeatability will be assessed using the Coefficient of Repeatability and the Intraclass Correlation Coefficient.
- Conditions
- Glaucoma
- Keywords
- Contrast Sensitivity
- Medical subject headings
- Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthy controls | Healthy controls age 10 to 90 years |
What is being measured
The primary outcome is the main question the study is designed to answer.
SPARCS results
Results from each eyes response to the contrast sensitivity test
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2015 (estimated)
- Study startAug 2012
- Primary completionAug 2015
- Study completionAug 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 208 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Wills Eye
- Sponsor type
- University, hospital or other
- Collaborators
- Partridge Foundation
- Responsible party
- Principal investigator, George L. Spaeth MD, Wills Eye
- Investigators
- George L Spaeth, MD, Principal investigator, Medical Director, Glaucoma Research Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02627339
- Sponsor's protocol ID
- 12-234E
- Acronym
- SPARCS
- Status last verified
- Nov 2016
- First submitted
- 8 Dec 2015
- Last updated
- 21 Nov 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Richman J, Spaeth GL, Wirostko B. Contrast sensitivity basics and a critique of currently available tests. J Cataract Refract Surg. 2013 Jul;39(7):1100-6. doi: 10.1016/j.jcrs.2013.05.001. Epub 2013 May 23.
PubMed 23706926
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Study of Controls to Build a Normative Database for the Spaeth/Richman Contrast Sensitivity Test (SPARCS)
- ClinicalTrials.gov ID
- NCT02627339
- Acronym / sponsor ID
- SPARCS / 12-234E
- Conditions
- Glaucoma
- Keywords
- Contrast Sensitivity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 208 participants (actual)
- Lead sponsor
- Wills EyeUniversity, hospital or other
- Collaborators
- Partridge Foundation
- Study start
- Aug 2012
- Primary completion
- Aug 2015 (actual)
- Study completion
- Aug 2015 (actual)
- First posted
- 10 Dec 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to build a database of results from a new test that measures contrast sensitivity (the Spaeth-Richman Contrast Sensitivity Test (SPARCS)). Contrast sensitivity is an important part of your ability to see. When contrast sensitivity decreases, you are less able to see objects and detect motion. For instance, if you have decreased contrast sensitivity, you might be less able to read, see in the dark, drive, hit a ball, or walk safely. Decrease in contrast sensitivity leads to a decrease in quality of life.
Detailed description
Objective: To build a normative database for the Spaeth / Richman Contrast Sensitivity Test (SPARCS).
Background: Patients with glaucoma have diminished contrast sensitivity. SPARCS is a novel test designed to determine the contrast threshold in the central 5 degrees of vision as well as each of the 4 peripheral quadrants (superotemporal, superonasal, inferotemporal, inferonasal). It is performed on a standard computer with at least 1024 x 768 monitor resolution. The correct testing distance is 50 cm away from the computer screen. Appropriate refractive correction is used. Testing is performed in a room with standardized lighting (85 cd / m2) and no windows in order to minimize glare and reflections. Testing is performed monocularly with the non-tested eye covered by an eye patch. The purpose of this study is to build a normative database for SPARCS.
Study Design: Cross sectional observational study.
Methods: Healthy volunteers will be recruited from the Wills Eye Institute after obtaining informed consent following the principles of the Helsinki Convention. Approximately 320 people free of ocular disease will be recruited to form a portion of the normative database for SPARCS. A goal of 20 subjects per decade of life (10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+) for both Caucasians and African Americans will be recruited. Other ethnicities will also be recruited, though without specific recruitment goals. Future study locations will help diversify the population of the normative database.
After agreeing to participate in the study, subjects will be assessed to determine if they qualify. Potential participants will be asked if they have any known eye diseases or decreased vision. Best-corrected monocular visual acuities will be assessed using an ETDRS visual acuity chart. A slit lamp examination will be performed to confirm good ocular health. Subjects will be excluded if they have any apparent ocular disease that affects visual acuity or visual function. For example, people with glaucoma, macular degeneration, or diabetic retinopathy will be excluded. Additional exclusion criteria includes: visual acuity 20/40 or worse; cataract grade 2 3+ or worse; posterior capsular opacity grade 2 3+ or worse; refractive error greater than +5 or -5 diopters; and incisional eye surgery within the prior 3 months.
After a person qualifies for the normative database, he or she will then take SPARCS. A trained technician will position the patient to the correct testing distance, check room lighting, and then explain the test. Subjects will be told to fixate on the central area and when ready, click the central area once with a computer mouse. Vertical dark bars will briefly appear in 1 of the 5 tested areas on the computer monitor. A subject will then move the mouse to the area the image appeared and click it once. When the subject is ready for the next image to appear, he or she will click again on the central area. Subjects are also instructed to guess where the image appeared if unsure. Vertical square waves of varying contrast levels will then continue to appear in a random pattern until threshold has been reached for each area. After the testing algorithm has been completed, the test will automatically end.
Each eye of an eligible subject will take the test twice after receiving instructions from a technician. The technician will remain in the testing room the first two times SPARCS is taken. A half hour later, the subject will then take SPARCS again without instructions from the technician and without the technician being present in the room.
The mean score and standard deviation of each area and the total score will be analyzed for age, gender, race, and lens status. Spearman correlations will be used to examine continuous variables and Kruskal-Wallis analysis for categorical measures. Test-retest repeatability will be assessed using the Coefficient of Repeatability and the Intraclass Correlation Coefficient.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Healthy controls | – | –Healthy controls age 10 to 90 years |
Who may qualify
- Ages
- 10 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Healthy controls with no eye diseases
Key inclusion criteria (2 listed)
- 10 years or older and healthy
- No eye diseases
Key exclusion criteria (4 listed)
- Patients with glaucoma, macular degeneration, diabetic retinopathy, corneal disease, eye movement disorders or any eye disease causing vision loss
- Patients with visual acuity worse than 20/40
- Patients with cataracts or opacities 2+ or greater
- Patients with refractive error +6 -6 or greater
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
SPARCS results
Time frame: 1 day
Results from each eyes response to the contrast sensitivity test
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2016.
- Background: PubMed 23706926Richman J, Spaeth GL, Wirostko B. Contrast sensitivity basics and a critique of currently available tests. J Cataract Refract Surg. 2013 Jul;39(7):1100-6. doi: 10.1016/j.jcrs.2013.05.001. Epub 2013 May 23.
- Individual participant dataSharing planned: No
Related trials for Glaucoma
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Not yet recruiting
AI-Assisted vs Conventional Teleglaucoma Referral
Glaucoma
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Recruiting
Automated Applanation Tonometry - Updated
Glaucoma, Glaucoma, Suspect
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
George L Spaeth, MD principal investigator
Medical Director, Glaucoma Research Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glaucoma, run by Wills Eye at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SPARCS results (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02627339, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2016.